Supplementary Figures

Published: 4 August 2020| Version 1 | DOI: 10.17632/j7dfkr2s8v.1
Contributor:
Shintaro Akiyama

Description

Figure S1. Funnel plot of the studies that assessed the risk of respiratory tract infections with IL-12/23 and IL-23 antagonists. Begg’s test P = 0.67; Egger’s tests P = 0.065. Figure S2. Meta-analysis of Mantel Haenszel risk difference of respiratory tract infections (RTIs) with IL-12/23 and IL-23 antagonists to assess the differential risk of RTIs by underlying autoimmune diseases. Figure S3. (A) Meta-analysis of Mantel Haenszel risk difference of upper respiratory tract infections with IL-12/23 and IL-23 antagonists. (B) Funnel plot of the studies that assessed the risk of upper respiratory tract infections with IL-12/23 and IL-23 antagonists. Begg’s test P = 0.81; Egger’s tests P = 0.46. Figure S4. (A) Meta-analysis of Mantel Haenszel risk difference of viral upper respiratory tract infections with IL-12/23 and IL-23 antagonists. (B) Funnel plot of the studies that assessed the risk of viral upper respiratory tract infections with IL-12/23 and IL-23 antagonists. Begg’s test P < 0.001; Egger’s tests P = 0.019. Figure S5. (A) Meta-analysis of Mantel Haenszel risk difference of lower respiratory tract infections with IL-12/23 and IL-23 antagonists. (B) Funnel plot of the studies that assessed the risk of lower respiratory tract infections with IL-12/23 and IL-23 antagonists. Begg’s test P < 0.001; Egger’s tests P = 0.55. Figure S6. Funnel plot of the studies that assessed the risk of infectious pneumonia with IL-12/23 and IL-23 antagonists. Begg’s test P < 0.001; Egger’s tests P = 0.93. Figure S7. Funnel plot of the studies that assessed the risk of non-infectious ILD with IL-12/23 and IL-23 antagonists. Begg’s test P < 0.001; Egger’s tests P = 0.69.

Files